Citations

Clear

623 citation(s) found for "Torres, V".

Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations
Itan, Michal, Grass, Daniel, Gordon, Yaara , Dolitzky, Avishay, Hazut, Inbal, Avlas, Shmuel , Jacobsen, Elizabeth A. , Ziv‐Baran, Tomer , Munitz, Ariel , Munitz, Ariel , Jacobsen, Elizabeth A , Grisaru‐Tal, Sharon , Torres–Roca, Javier F. , Eschrich, Steven A

Mayo Clinic

OncoImmunology | December 31, 2020 | Volume: 10 | Issue: 1 | Pages: No page available

10.1080/2162402x.2020.1859732 | PMID 33457078 Get It

International Delphi Expert Consensus on Safe Return to Surgical and Endoscopic Practice
Asbun, Horacio J. , Hilal, Mohammad Abu , Kunzler, F. , Asbun, Domenech , Bonjer, Jaap, Conlon, Kevin, Feldman, LS, Morales‐Conde, Salvador , Pietrabissa, Andrea , Schlachta, Christopher M. , Sylla, Patricia , Targarona, Eduardo M. , Agra, Yolanda, Callery, Mark P., Cleary, SP, ́Cruz, Len D, Eckert, Philippe, Evans, Chad, Hs, Han, Jones, DB, Gan, TJ, Koch, Daniel, Lillemoe, K. D., Lomanto, D, Marks, Jeffrey, Matthews, Brent, Mellinger, John, Melvin, WS, Moreno-Paquentin, E, Navarrete, Claudio , Pawlik, TM, Pessaux, Patrick , Schwaitzberg, Steven D. , Shah, Paresh, Szokol, Joseph W., Talamini, Mark A., Torres, Rosa Del Pilar Uriarte , Triboldi, Alessandro, Udomsawaengsup, Suthep , Valsecchi, Federica, Vauthey, JN, Wallace, Michael, Sd, Wexner, Zinner, Michael J. , Wallace, Michael B. , Wexner, Steven D. , Cleary, Sean P. , Wallace, Michael B , Wexner, Steven D , Morales-Conde, Salvador , Bonjer, Hendrik Jaap , Conlon, Kevin, Demartines, Nicolas , Feldman, Liane S. , Pryor, Aurora Dawn , Agra, Yolanda, Besselink, Marc G , Eckert, Philippe, Evans, Chad, Jones, Daniel B, Gan, Tong J. , Koch, Daniel, Marks, Jeffrey, Matthews, Brent, Mellinger, John, Melvin, William Scott , Moreno-Paquentín, Eduardo, Pawlik, Timothy M , Ricciardi, Walter , Shah, Paresh, Torres, Ricardo, Wallace, Michael, Francis, Nader Kamal

Mayo Clinic

Annals of Surgery | December 31, 2020 | Volume: 274 | Issue: 1 | Pages: 50-56

10.1097/sla.0000000000004674 | PMID 33630471 Get It

Objective: The aim of this work is to formulate recommendations based on global expert consensus to guide the surgical community on the safe resumption of surgical and endoscopic activities. Background: The COVID-19 pandemic has caused marked disruptions in the delivery of surgical care worldwide. A thoughtful, structured approach to resuming surgical services is necessary as the impact of COVID-19 becomes better controlled. The Coronavirus Global Surgical Collaborative sought to formulate, through rigorous scientific methodology, consensus-based recommendations in collaboration with a multidisciplinary group of international experts and policymakers. Methods: Recommendations were developed following a Delphi process. Domain topics were formulated and subsequently subdivided into questions pertinent to different aspects of surgical care in the COVID-19 crisis. Forty-four experts from 15 countries across 4 continents drafted statements based on the specific questions. Anonymous Delphi voting on the statements was performed in 2 rounds, as well as in a telepresence meeting. Results: One hundred statements were formulated across 10 domains. The statements addressed terminology, impact on procedural services, patient/staff safety, managing a backlog of surgeries, methods to restart and sustain surgical services, education, and research. Eighty-three of the statements were approved during the first round of Delphi voting, and 11 during the second round. A final telepresence meeting and discussion yielded acceptance of 5 other statements. Conclusions: The Delphi process resulted in 99 recommendations. These consensus statements provide expert guidance, based on scientific methodology, for the safe resumption of surgical activities during the COVID-19 pandemic.
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Torres, Vicente E. , Chapman, Arlene B., Devuyst, Olivier , Gansevoort, Ron T. , Perrone, Ronald D. , Lee, Jennifer , Hoke, Molly E., Estilo, Alvin, Sergeyeva, Olga, Torres, Vicente E , Torres, Vicente E , Devuyst, Olivier; https://orcid.org/0000-0003-3744-4767

Mayo Clinic

Clinical Journal of the American Society of Nephrology | December 29, 2020 | Volume: 16 | Issue: 1 | Pages: 48-58

10.2215/cjn.10250620 | PMID 33376102 Get It

Background and objectives Tolvaptan slows kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4, 2-year extension to TEMPO 3:4 (TEMPO 4:4), and 1-year Replicating Evidence of Preserved Renal Function: An Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, aquaretic adverse events were common. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations occurred in all three studies. Three patients met Hy Law criteria (ALT or AST more than three times and total bilirubin more than two times the upper limit of normal) for severe drug-induced liver injury (two in TEMPO 3:4 and one in TEMPO 4:4). In REPRISE, liver enzyme monitoring frequency was increased to monthly, with no Hy Law cases. A long-term, phase 3 safety study has further characterized tolvaptan safety. Design, setting, participants, & measurements Subjects who completed TEMPO 4:4, REPRISE, or other tolvaptan trials could enroll in this prospective, multinational, open-label safety study. Assessments included monthly liver enzyme testing during the first 18 months of tolvaptan exposure and every 3 months thereafter. Results Among 1803 subjects, median tolvaptan exposure during the extension was 651 days (interquartile range, 538–924), and cumulative exposure (extension and previous trials) was ≤11 years. Subjects entering from REPRISE placebo experienced more aquaretic adverse events compared with subjects from TEMPO 4:4 or REPRISE tolvaptan ( i.e ., patients with prior long-term tolvaptan exposure). Liver enzyme elevations also occurred more frequently in subjects from REPRISE placebo. Percentages experiencing ALT ≥3/≥5/ ≥10/≥20 times the upper limit of normal were 3.2%/2.1%/0.9%/0.7%, respectively, in subjects from REPRISE placebo and 0.6%–1.1%/0.0%–0.1%/0%/0%, respectively, in those from REPRISE tolvaptan and TEMPO 4:4. Percentages experiencing AST ≥3/ ≥5/≥10/≥20 times the upper limit of normal were 6.9%/3.8%/2.3%/0.8%, respectively, in subjects from REPRISE placebo and 0.9%–2.0%/0.0%–1.0%/0%/0%, respectively, in those from REPRISE tolvaptan and TEMPO 4:4. No Hy Law cases occurred. Conclusions No new safety signals emerged during this long-term extension. Monthly liver function testing for the first 18 months of treatment appeared to enable effective detection and management of transaminase elevations. Clinical Trial registry name and registration number: Open Label Extension of TEMPO 3:4, NCT02251275
Impact of a Systematic Pharmacist-Initiated Antibiotic Time-Out Intervention for Hospitalized Adults
Paulson, Calley M., Handley, Jillian F., Persells, Dan, Prusi, Rachael, Brummitt, Charles, Torres, Katherine Milagros Gómez, Skrupky, Lee P. , Dilworth, Thomas J , Skrupky, Lee P , Torres, Katherine M.

Mayo Clinic

Journal of Pharmacy Practice | December 23, 2020 | Volume: 35 | Issue: 3 | Pages: 388-395

10.1177/0897190020980616 | PMID 33353452 Get It

Introduction: Antibiotic time-outs (ATO) are a recommended antimicrobial stewardship action, but data assessing their impact are lacking. This study investigated the impact of a systematic, pharmacist initiated ATO intervention. Methods: This pre-post study included inpatients on hospitalist and intensivist services receiving empiric antibiotics for ≥48 hours. The ATO was initiated by pharmacists after 48 hours of empiric therapy and the outcome was documented including antibiotic indication, plan, and duration. An electronic medical record (EMR) alert facilitated ATO completion and pharmacists and prescribers received education prior to implementation. The primary outcome was EMR documentation of an antibiotic plan by 72 hours. Secondary outcomes included antibiotic utilization and antibiotic therapy modifications by 2 hours. Results: 399 patients were included, 199 pre- and 200 post-intervention. The most common indications were pneumonia (32%), intra-abdominal infection (20%) and urinary tract infection (19%), with no between-group differences. EMR documentation of an antibiotic plan significantly improved in the post-intervention group (19% vs. 79%, p<0.0001) as did modifications to antibiotic therapy. The median duration of in-hospital antibiotic therapy was similar between groups (4.0 vs. 4.0 days, p = 0.2499). Approximately 45% of patients in each group received discharge antibiotics and median duration of discharge antibiotic therapy prescribed was reduced (7 vs. 5 days in the pre- and post-intervention groups, respectively; p = 0.0140). Discussion: Implementation of pharmacist initiated ATO was associated with improvements in supporting EMR documentation and antibiotic therapy modifications. These findings highlight an important role in which pharmacists can serve as part of a collaborative antibiotic stewardship team.
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
Gerds, Aaron T. , Savona, Michael R. , Scott, Bart L. , Egyed, Miklós , Harrison, Claire , Yacoub, Abdulraheem , Vannucchi, Alessandro M. , Mead, Adam J. , O’Sullivan, Jennifer , García‐Gutiérrez, Valentín , Rampal, Raajit K. , Miller, Carole B., Palmer, Jeanne , Buckley, Sarah , Mould, Diane R. , Ito, Kaori , Tyavanagimatt, Shanthakumar , Roman‐Torres, Karisse, Devineni, Sri, Craig, Adam R., Vannucchi, Alessandro M , Gerds, Aaron T , Savona, Michael R , Mead, Adam J , Talpaz, Moshe , Kiladjian, Jean‐Jacques , Bose, Prithviraj , Oh, Stephen T. , Smith, Jennifer A. , Mascarenhas, John

Mayo Clinic

Blood Advances | December 3, 2020 | Volume: 4 | Issue: 22 | Pages: 5825-5835

10.1182/bloodadvances.2020003314 | PMID 33232476 Get It

Abstract PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced eligibility criteria, monitoring, and dose modifications were implemented to mitigate risk of cardiac and hemorrhagic events. Efficacy was based on ≥35% spleen volume response (SVR) and ≥50% reduction in the 7-component total symptom score (TSS) through week 24. Of 161 patients, 73% were intolerant of and 76% had become resistant to ruxolitinib; 50% met criteria for both. Severe thrombocytopenia (platelet count &lt;50 × 103/μL) was present in 44%. SVR rates were highest with 200 mg twice per day (100 mg once per day, 0%; 100 mg twice per day, 1.8%; 200 mg twice per day, 9.3%), particularly among patients with baseline platelet counts &lt;50 × 103/μL (17%; 4 of 24). Although TSS response rate was similar across doses (100 mg once per day, 7.7%; 100 mg twice per day, 7.3%; 200 mg twice per day, 7.4%), median percent reduction in TSS suggested a dose-response relationship (–3%, −16%, and −27%, respectively). Pharmacokinetic and pharmacodynamic modeling based on all available data showed greatest SVR and TSS reduction at 200 mg twice per day compared with lower doses. Common adverse events were gastrointestinal events, thrombocytopenia, and anemia. There was no excess of grade ≥3 hemorrhagic or cardiac events at 200 mg twice per day. Pacritinib 200 mg twice per day demonstrated clinical activity and an acceptable safety profile and was selected as the recommended dose for a pivotal phase 3 study in patients with myelofibrosis and severe thrombocytopenia. This trial was registered at www.clinicaltrials.gov as #NCT03165734.
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
Ansell, Stephen M. , Barnes, Jeffrey A. , Clemens, Mark W. , Goodman, Aaron M. , Guitart, Joan , Haverkos, Bradley M. , Hoppe, Richard T. , Jacobsen, Eric D. , Jagadeesh, Deepa , Jones, Allison , Mehta–Shah, Neha , Olsen, Elise A. , Pro, Barbara, Rajguru, Saurabh, Rozati, Sima , Said, Jonathan , Shaver, Aaron C., Shustov, Andrei R., Sokol, Lubomir , Torka, Pallawi , Torres‐Cabala, Carlos A. , William, Basem M. , Zain, Jasmine , Dwyer, Mary A., Sundar, Hema, William, Basem , Torres-Cabala, Carlos , Hoppe, Richard T , Horwitz, Steven M. , Ai, Weiyun Z. , Barta, Stefan K , Doǧan, Ahmet , Goyal, Gaurav , Halwani, Ahmad , Kim, Youn H , Sokol, Lubomir , Wilcox, Ryan A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 5, 2020 | Volume: 18 | Issue: 11 | Pages: 1460-1467

10.6004/jnccn.2020.0053 | PMID 33152703 Get It

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.
Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease
Wong, Annette , Munt, Alexandra , Allman‐Farinelli, Margaret , Badve, Sunil V. , Boudville, Neil , Coolican, Helen, Chandra, Ashley N. , Coulshed, Susan, Fernando, Mangalee, Grantham, Jared J. , Haloob, Imad, Harris, David C.H. , Holt, Jane L., Johnson, David W. , Kumar, Karthik, Lee, Vincent , Lonergan, Maureen , Mai, Jun, Rangan, Anna , Roger, Simon D. , Saravanabavan, Sayanthooran , Sud, Kamal , Torres, Vicente E. , Vilayur, Eswari, Zhang, Jennifer Q. J. , Rangan, Gopala K. , Johnson, David W , Lee, Vincent W , Rangan, Anna , Sud, Kamal , Zhang, Jennifer Q J , Torres, Vicente E , Hawley, Carmel M.

Mayo Clinic

Nutrients | November 2, 2020 | Volume: 12 | Issue: 11 | Pages: 3376

10.3390/nu12113376 | PMID 33147804 Get It

The excess intake of dietary sodium is a key modifiable factor for reducing disease progression in autosomal dominant polycystic kidney disease (ADPKD). The aim of this study was to test the hypothesis that the scored salt questionnaire (SSQ; a frequency questionnaire of nine sodium-rich food types) is a valid instrument to identify high dietary salt intake in ADPKD. The performance of the SSQ was evaluated in adults with ADPKD with an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 during the screening visit of the PREVENT-ADPKD trial. High dietary sodium intake (HSI) was defined by a mean 24-h urinary sodium excretion ≥ 100 mmol/day from two collections. The median 24-h urine sodium excretion was 132 mmol/day (IQR: 112–172 mmol/d) (n = 75; mean age: 44.6 ± 11.5 years old; 53% female), and HSI (86.7% of total) was associated with male gender and higher BMI and systolic blood pressure (p < 0.05). The SSQ score (73 ± 23; mean ± SD) was weakly correlated with log10 24-h urine sodium excretion (r = 0.29, p = 0.01). Receiving operating characteristic analysis showed that the optimal cut-off point in predicting HSI was an SSQ score of 74 (area under the curve 0.79; sensitivity 61.5%; specificity 90.0%; p < 0.01). The evaluation of the SSQ in participants with a BMI ≥ 25 (n = 46) improved the sensitivity (100%) and the specificity (100%). Consumers with an SSQ score ≥ 74 (n = 41) had higher relative percentage intake of processed meats/seafood and flavourings added to cooking (p < 0.05). In conclusion, the SSQ is a valid tool for identifying high dietary salt intake in ADPKD but its value proposition (over 24-h urinary sodium measurement) is that it may provide consumers and their healthcare providers with insight into the potential origin of sodium-rich food sources.
Prenatal assessment of congenital diaphragmatic hernia at north american fetal therapy network centers: A continued plea for standardization
Perrone, Erin E. , Abbasi, Nimrah , Umar, Uzma, Johnson, Anthony , Ladino-Torres, Maria, Ruano, Rodrigo , (NAFTNet), North American Fetal Therapy Network, Papanna, Ramesha , Cortes, Magda Sanz , Ruano, Rodrigo , Perrone, Erin E , Ryan, Greg , (NAFTNet), North American Fetal Therapy Network, Papanna, Ramesha

Mayo Clinic

Prenatal Diagnosis | October 30, 2020 | Volume: 41 | Issue: 2 | Pages: 200-206

10.1002/pd.5859 | PMID 33125174 Get It

AbstractIntroductionPrenatal work‐up for congenital diaphragmatic hernia (CDH) is important for risk stratification, standardization, counseling, and optimal therapeutic choice. To determine current practice patterns regarding prenatal CDH work‐up, including prenatal ultrasound and magnetic resonance imaging (MRI) use, and to identify areas for standardization of such evaluation between fetal centers.MethodsA survey regarding prenatal CDH work‐up was sent to each member center of the North American Fetal Therapy Network (NAFTNet) (n = 36).ResultsAll responded. Sonographic measurement of lung‐to‐head ratio (LHR) was determined by all, 89% (32/36) of which routinely calculate observed‐to‐expected LHR. The method for measuring LHR varied: 58% (21/36) used a “trace” method, 25% (9/36) used “longest axis,” and 17% (6/36) used an “antero‐posterior” method. Fetal MRI was routinely used in 78% (28/36) of centers, but there was significant variability in fetal lung volume measurement. Whereas all generated a total fetal lung volume, the planes, methodology and references values varied significantly. All evaluated liver position, 71% (20/28) evaluated stomach position and 54% (15/28) quantified the degree of liver herniation. More consistency in workup was seen between centers offering fetal intervention.ConclusionPrenatal CDH work‐up and management differs considerably among North American fetal diagnostic centers, highlighting a need for its standardization.
International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality monitors
Illingworth, Andrea , Johansson, Ulrika , Huang, Shuguang , Wang, Sa A. , Wolniak, Kristy , Psarra, Katherina , Torres, Richard , Craig, Fiona E. , Horna, Pedro , Craig, Fiona E , Almeida, Júlia

Mayo Clinic

Cytometry Part B: Clinical Cytometry | October 28, 2020 | Volume: 100 | Issue: 2 | Pages: 156-182

10.1002/cyto.b.21963 | PMID 33112044 Get It

AbstractIntroducing a sensitive and specific peripheral blood flow cytometric assay for Sézary syndrome and mycosis fungoides (SS/MF) requires careful selection of assay design characteristics, and translation into a laboratory developed assay through development/optimization, validation, and continual quality monitoring. As outlined in a previous article in this series, the recommended design characteristics of this assay include at a minimum, evaluation of CD7, CD3, CD4, CD8, CD26, and CD45, analyzed simultaneously, requiring at least a 6 color flow cytometry system, with both quantitative and qualitative components. This article provides guidance from an international group of cytometry specialists in implementing an assay to those design specifications, outlining specific considerations, and best practices. Key points presented in detail are: (a) Pre‐analytic components (reagents, specimen processing, and acquisition) must be optimized to: (i) identify and characterize an abnormal population of T‐cells (qualitative component) and (ii) quantitate the abnormal population (semi/quasi‐quantitative component). (b)Analytic components (instrument set‐up/acquisition/analysis strategy and interpretation) must be optimized for the identification of SS/MF populations, which can vary widely in phenotype. Comparison with expert laboratories is strongly encouraged in order to establish competency. (c) Assay performance must be validated and documented through a validation plan and report, which covers both qualitative and semi/quasi‐quantitative assay components (example template provided). (d) Ongoing assay‐specific quality monitoring should be performed to ensure consistency.
A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease
Blazer‐Yost, Bonnie L. , LaPradd, Michelle, Edwards, Marie E., Sheth, Nehal, Swinney, Kim, Ponsler-Sipes, Kristen, Moorthi, Ranjani N. , Perkins, Susan M. , Torres, Vicente E. , Torres, Vicente E , Bacallao, Robert L. , Erickson, Bradley J. , Moe, Sharon M.

Mayo Clinic

Clinical Kidney Journal | October 27, 2020 | Volume: 14 | Issue: 7 | Pages: 1738-1746

10.1093/ckj/sfaa232 | PMID 34221381 Get It

Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common monogenetic disorders in humans and is characterized by numerous fluid-filled cysts that grow slowly, resulting in end-stage renal disease in the majority of patients. Preclinical studies have indicated that treatment with low-dose thiazolidinediones, such as pioglitazone, decrease cyst growth in rodent models of PKD. Methods This Phase 1b cross-over study compared the safety of treatment with a low dose (15 mg) of the peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist pioglitazone or placebo in PKD patients, with each treatment given for 1 year. The study monitored known side effects of PPAR-γ agonist treatment, including fluid retention and edema. Liver enzymes and risk of hypoglycemia were assessed throughout the study. As a secondary objective, the efficacy of low-dose pioglitazone was followed using a primary assessment of total kidney volume (TKV), blood pressure (BP) and kidney function. Results Eighteen patients were randomized and 15 completed both arms. Compared with placebo, allocation to pioglitazone resulted in a significant decrease in total body water as assessed by bioimpedance analysis {mean difference 0.16 Ω [95% confidence interval (CI) 0.24–2.96], P = 0.024} and no differences in episodes of heart failure, clinical edema or change in echocardiography. Allocation to pioglitazone led to no difference in the percent change in TKV of −3.5% (95% CI −8.4–1.4, P = 0.14), diastolic BP and microalbumin:creatinine ratio. Conclusions In this small pilot trial in people with ADPKD but without diabetes, pioglitazone 15 mg was found to be as safe as placebo. Larger and longer-term randomized trials powered to assess effects on TKV are needed.